Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective β3-adrenoceptor agonist

Xenobiotica

Volumn 42, Issue 10, 2012, Pages 957-967

  Takusagawa, Shin ^a   Yajima, Kanako ^b   Miyashita, Aiji ^a   Uehara, Shotaro ^b   Iwatsubo, Takafumi ^a   Usui, Takashi ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

Author keywords

Butyrylcholinesterase; CYP2D6; CYP3A4

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR; CHOLINESTERASE; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ESTERASE; MIRABEGRON; TESTOSTERONE;

ARTICLE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROXYLATION; INTESTINAL MICROSOME; INTESTINE; LIVER MICROSOME; MICROSOME; PROTEIN ANALYSIS;

ACETANILIDES; ACETYLCHOLINESTERASE; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ANTIBODIES, MONOCLONAL; BUTYRYLCHOLINESTERASE; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; ESTERASES; FEMALE; HUMANS; HYDROLYSIS; IMMUNE SERA; ISOENZYMES; KINETICS; LIVER; MALE; MICROSOMES, LIVER; OXYGENASES; RECEPTORS, ADRENERGIC, BETA-3; RECOMBINANT PROTEINS; SOLUTIONS; THIAZOLES;

EID: 84865852131     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.675095     Document Type: Article

References (31)

1. Berry LM, Wollenberg L, Zhao Z. (2009). Esterase activities in the blood, liver and intestine of several preclinical species and humans. Drug Metab Lett 3:70-77.
2. Costello PB, Green FA. (1982). Aspirin survival in human blood modulated by the concentration of erythrocytes. Arthritis Rheum 25:550-555.
3. Gonzalez FJ, Gelboin HV. (1994). Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 26:165-183.
4. Imai T. (2006). Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 21:173-185.
5. Jones HM, Houston JB. (2004). Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab Dispos 32:973-982.
6. Khullar V, Cambronero J, Ströberg P, Angulo J, Boerrigter P, Blauwet MB, Wooning M. (2011). The efficacy and tolerability of mirabegron in patients with overactive bladder - results from a European- Australian Phase III trial. Eur Urol Suppl 10:278-279.
7. Kitamura A, Mizuno Y, Natsui K, Yabuki M, Komuro S, Kanamaru H. (2005). Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone. Biopharm Drug Dispos 26:59-65.
8. Li B, Sedlacek M, Manoharan I, Boopathy R, Duysen EG, Masson P, Lockridge O. (2005). Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 70:1673-1684.
9. Lin JH, Lu AY. (1998). Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35:361-390.
10. Minagawa T, Kohno Y, Suwa T, Tsuji A. (1995). Species differences in hydrolysis of isocarbacyclin methyl ester (TEI-9090) by blood esterases. Biochem Pharmacol 49:1361-1365.
11. Morgan EW, Yan B, Greenway D, Parkinson A. (1994). Regulation of two rat liver microsomal carboxylesterase isozymes: species differences, tissue distribution, and the effects of age, sex, and xenobiotic treatment of rats. Arch Biochem Biophys 315:513-526.
12. Mutch E, Nave R, McCracken N, Zech K, Williams FM. (2007). The role of esterases in the metabolism of ciclesonide to desisobutyrylciclesonide in human tissue. Biochem Pharmacol 73:1657-1664.
13. Nitti V, Herschorn S, Auerbach S, Ayers M, Lee M, Martin N. (2011). The efficacy and safety of mirabegron in patients with overactive bladder syndrome - results from a North-American Phase III trial. Eur Urol Suppl 10:278.
14. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. (2004). The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193-209.
15. Pearce RE, Rodrigues AD, Goldstein JA, Parkinson A. (1996). Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 277:805-816.
16. Reiner E, Bosak A, Simeon-Rudolf V. (2004). Activity of cholinesterases in human whole blood measured with acetylthiocholine as substrate and ethopropazine as selective inhibitor of plasma butyrylcholinesterase. Arh Hig Rada Toksikol 55:1-4.
17. Rodrigues AD. (1999). Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNAexpressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465-480.
18. Sawamoto T, Lee J, Alak A, Meijer J, Roy M, Zha J, van Gelderen M, Marion A, Keirns J. (2011). Phase I, open-label, drug interaction study to evaluate the effect of multiple doses of ketoconazole on single dose mirabegron (YM178) oral controlled absorption system (OCAS) in healthy adult subjects. Clin Pharmacol Ther 89:S21.
19. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
20. Singh SS. (2006). Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr Drug Metab 7:165-182.
21. Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O. (2007). Effect of R-2-(2- aminothiazol-4-yl)- 4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642-647.
22. Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, Usui T. (2012). Absorption, metabolism and excretion of [14C] mirabegron (YM178), a potent and selective β3-adrenoceptor agonist, after oral administration to healthy male volunteers. Drug Metab Dispos Jan 23 Drug Metab Dispos 40:815-824.
23. U.S. Department of Health and Human Services Food and Drug Administration. (2006). Guidance for Industry In vivo drug metabolism/drug interaction studies Study design, data analysis, and recommendations for dosing and labeling
24. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research Center for Biologics Evaluation and Research.
25. van Gelderen EM, Li Q, Meijer J, Schaddelee MP, Takusagawa S, Sugawara T, de Koning P. (2009). An exploratory comparison of the single dose pharmacokinetics of the β3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers. Clin Pharmacol Ther 85:S88.
26. van Teijlingen R, Meijer J, Takusagawa S, van Gelderen M, van den Beld C, Usui T. (2012). Development and validation of LC-MS/MS methods for the determination of mirabegron and its metabolites in human plasma and their application to a clinical pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 887-888:102-111.
27. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M. (2003). Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761.
28. Whittaker M. (1980). Plasma cholinesterase variants and the anaesthetist. Anaesthesia 35:174-197.
29. Yamaguchi O, Chapple CR. (2007). Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn 26:752-756.
30. Yamaori S, Ukena E, Fujiyama N, Funahashi T, Kimura T, Yamamoto I, Ohshima T, Matsumura K, Oda M, Watanabe K. (2007). Nafamostat is hydrolysed by human liver cytosolic long-chain acyl-CoA hydrolase. Xenobiotica 37:260-270.
31. Yan R, Fokina V, Hankins GD, Ahmed MS, Nanovskaya TN. (2008). The effect of esterases on 17α-hydroxyprogesterone caproate. Am J Obstet Gynecol 198:229.e1-229.e5.